| Thursday,
June 5, 2008 |
| Noon- 7:00 PM |
Registration |
| 6:00 - 8:00 PM |
Welcome Wine and Cheese Reception for all Attendees and Exhibitors-
Poolside |
| |
|
|
|
| Friday,
June 6, 2008 |
| 7:00-8:00 AM |
BREAKFAST in the Exhibits (On
site registration available) |
| 8:00-9:40
AM |
SESSION
I: |
Transplantation
of Adults; Double Cord Blood Transplants; Reduced Intensity Cord Blood
Transplants |
| |
|
Chairpersons: |
Joseph Antin, M.D.
John Wagner, M.D. |
| |
8:00 - 8:20 AM |
Progress in Umbilical Cord Blood Transplantation “From
Zero to 10,000”
John Wagner, MD, University of Minnesota, Minneapolis, MN |
| |
8:20 - 8:35 AM |
Double Cord Blood
Transplants – State
of the Art.
Claudio
Brunstein, M.D., University of Minnesota, Minneapolis, MN |
| |
8:35 - 8:50 AM |
CD34+ viability is a critical determinant
of the
engraftment potential of UCB in double unit
transplantation.
Machi Scaradavou, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY |
| |
8:50 - 9:05 AM |
Double UCBT with reduced intensity
conditioning and Sirolimus-based GVHD
prophylaxis.
Joseph Antin, M.D., Dana-Farber
Cancer Institute, Boston, MA |
| |
9:05 - 9:20 AM |
Unrelated UCBT after reduced intensity
conditioning in adults with
hematologic malignancies - Combined data of
Eurocord and University of Minnesota.
Vanderson Rocha, M.D.,
Hôpital Saint-Louis, Paris, France |
| |
9:20 - 9:40 AM |
"Targeted" Panel Discussion
Moderators: Dr. Antin, Dr. Wagner
Panelists: Antin, Brunstein, Rocha, Scaradavou, Wagner |
| |
|
"Target Questions"
- How can we determine if double cord blood
transplants are superior to single cord
transplants?
- What are the current indications for double
cord transplants?
- What strategies can be used to select double cords for transplantation
to a single patient?
- Is GVHD increased in double cord blood
transplants?
- How do the GVHD incidence, severity and
responsiveness to treatment compare with PBSC and
BMT transplants?
- What is the potency of GVL after RIC. i.e., what is the efficacy
of RIC UCBT In different diseases?
- What are the optimal preparative regimens and
GVHD prevention regimens for reduced-intensity UCBT?
AND: Written questions from attendees (to be submitted at the Symposium) |
| 9:40 -10:00
AM |
SESSION II: |
Honoring the basic scientists and
clinicians who were pioneers in development of umbilical cord blood transplantation
on the 20th anniversary of the first cord blood transplant. |
| |
|
|
Introduced by UCB transplant recipients Matthew Farrow (recipient of the world's first CBT), Stephen Sprague and Jill Anderson. |
| 10:00 - 10:30
AM |
COFFEE BREAK in the Exhibits |
| 10:30 - 11:50
AM |
SESSION III: |
Cord Blood Selection, Processing and
Infusion |
| |
Chairpersons: |
Eliane Gluckman, M.D.
Juliet Barker, M.B.B.S. |
| |
10:30 - 10:45 AM |
Donor Selection in UCBT. Eliane
Gluckman. M.D., Hôpital Saint-Louis, Paris, France. |
| |
10:45 - 11:00 AM |
The dose-match interaction in
UCB transplantation: An analysis of the impact of cell dose and HLA-match
on the DFS of 989 patients transplanted with single units for hematologic
malignancy. Juliet Barker, M.B.B.S., Memorial Sloan-Kettering Cancer
Center, New York, NY |
| |
11:00 - 11:15 AM |
Post thaw CFUs and other graft
parameters that predict engraftment post-UCBT.
Joanne Kurtzberg, M.D.,
Duke University, Durham, NC |
| |
11:15 - 11:30 AM |
Is there more to cord blood units than cell dose?
Robert
Chow, M.D., StemCyte Cord International Blood Center, Covina, CA |
| |
11:30 -11:50 AM |
"Targeted" Panel Discussion
Moderators: Dr. Barker, Dr. Gluckman
Panelists: Barker, Chow, Gluckman, Kurtzberg |
| |
"Target Question"
- How does one balance cell dose and HLA match in unit selection?
- How can an individual transplant center incorporate results
of CFU and CD34+ assays performed on the UCB product post-thaw into
their clinical practice?
- Are cell doses described as pre-cryopreservation or pre-infusion?
- Is washing of units advisable?
AND: Written questions from attendees (to be submitted at the Symposium) |
| 11:50 AM - 1:00 PM |
LUNCH in the Exhibits |
| 1:00 - 2:40
PM |
SESSION IV: |
Overcoming Barriers to Transplantation - Facilitating
the Search for a Cord Blood Unit |
| |
|
Chairpersons: |
Richard Champlin, M.D.
Dennis Confer, M.D. |
| |
1:00 - 1:15 PM |
Trials and tribulations of the
cord blood search
process. Life from the perspective of the search
coordinator.
Michele Alvarez, Transplant Coordinator, MD Anderson
Cancer Center, Houston, TX |
| |
1:15 - 1:35 PM |
Evolution of the cord blood search process: Toward a better search.
Dennis Confer. M.D., National Marrow Donor Program, Minneapolis, MN |
| |
1:35 -1:55 PM |
Why patients with an indication
for
transplantation do not receive a transplant.
Richard Champlin, M.D., MD Anderson Cancer
Center, Houston, TX |
| |
1:55 - 2:15 PM |
Referring physicians attitudes
toward
transplantation.
Philip McCarthy, M.D., Roswell Park Cancer
Institute, Buffalo, NY |
| |
2:15 - 2:40 PM |
"Targeted" Panel
Discussion
Moderator: Dr. Champlin
Panelists: Alvarez, Confer, Champlin, McCarthy |
| |
"Target Questions"
- What are the major causes of under-utilization of
HSCT in general and UCBs in particular?
- Are the indications for HSCT generally well
defined?
- When should a transplant physician search for a cord blood unit?
- What
is the optimal mechanism by which to search for a CB unit?
- Can improvement in timeliness
of referrals result in improved outcomes?
AND: Written questions from attendees (to be
submitted at the Symposium) |
| 2:40 -3:00 PM |
COFFEE BREAK in the Exhibits |
| 3:00 - 4:00 PM |
SESSION V: |
Biology of Hematopoietic Cells |
| |
Chairperson: |
Hal Broxmeyer, Ph.D. |
| |
3:00 - 3:20 PM |
Influence of CD26 on cytokines
and chemokines involved in proliferation, survival and movement of hematopoietic
stem and progenitor cells.
Hal Broxmeyer, Ph.D., Indiana University School of Medicine, Indianapolis,
IN |
| |
3:20 - 3:40 PM |
E-type prostaglandins - multiple
effects on hematopoiesis.
Louis Pelus, Ph.D., Indiana University School
of Medicine Indianapolis, IN. |
| |
3:40 - 4:00 PM |
The role of the nervous system
in hematopoiesis.
Paul S. Frenette, M.D., Mount Sinai School of Medicine, New York,
NY. |
| 4:00 PM |
ADJOURN |
|
| |
|
|
| Saturday,
June 7, 2008 |
| 7:00-8:00 AM |
BREAKFAST in the Exhibits (Registration desk will be open for single-day registrations) |
| 8:00 AM - NOON |
SESSION VI: |
Basic Science and Clinical Studies Addressing Obstacles
to Successful UCBT |
| |
Chairpersons: |
John Wagner, M.D.
Kent Christopherson, Ph.D. |
| |
8:00 - 8:20 AM |
Introduction to the obstacles in UCB transplantation, and the basic science approaches to overcoming these obstacles; Characterization of engraftment after UCBT.
John Wagner, M.D.,
University of Minnesota, Minneapolis, MN |
Strategies to Improve Engraftment |
| |
8:20 - 8:40 AM |
Strategies to improve homing.
Kent Christopherson, Ph.D., Rush University Medical Center, Chicago,
IL |
| |
8:40 - 9:00 AM |
Fucosylation of cord blood CD34+
cells.
Patrick Zweidler-McKay, M.D., Ph.D., MD Anderson Cancer Center, Houston,
TX |
| |
9:00 - 9:20 AM |
Augmentation of unrelated donor umbilical cord blood transplantation with ALDHbr cells
Joanne Kurtzberg, M.D., Duke University, Durham, NC |
| 9:20 - 9:40 AM |
COFFEE BREAK in the
Exhibits |
| 9:40 AM - NOON |
SESSION
VI
(continued) |
Immune Reconstitution, Opportunistic Infections and GVHD |
| |
9:40 - 10:00 AM |
GVHD in UCBT
Daniel Weisdorf,
M.D., University of MN, Minneapolis, MN |
| |
10:00 - 10:20 AM |
Chronic graft-versus-host disease
following unrelated donor vs. UCB transplants: higher response rate in
recipients of umbilical cord blood.
Mukta Arora, M.D., University of MN, Minneapolis, MN |
| |
10:20 - 10:40 AM |
Biology of Immune Reconstitution.
Bruce Blazar, M.D., University of MN, Minneapolis, MN |
| |
10:40 - 11:00 AM |
Characterization of immune recovery
and its relevance regarding opportunistic infections after UCBT.
Paul Szabolcs, M.D., Duke
University, Durham, NC |
| |
11:00 - 11:20 AM |
Genetic modification of cord
blood T cells for anti-leukemic activity.
Gianpietro Dotti, M.D., Baylor
College of Medicine, Houston, Texas |
| |
11:20 - NOON |
"Targeted" Panel
Discussion
Moderators: Dr. Wagner, Dr. Christopherson, Dr. Veneris
Panelists: Arora, Blazar, Christopherson, Dotti, Kurtzberg, Szabolcs, Wagner,
Weisdorf, Zweidler- McKay |
| |
|
"Target Questions"
- What is the mechanism of retained GVL in UCBT given GVHD is
less severe?
- How significant are the reports of increased GVHD after
peripheral blood stem cell transplants?
- Is acute and chronic GVHD more responsive to therapy
after
UCBT than after unrelated donor BMT or PBSC?
- Are cellular therapies
to improve engraftment and immune
recovery nearing clinical application?
AND: Written questions from attendees (to be submitted at the Symposium) |
| NOON - 1:15 PM |
LUNCH in the Exhibits |
| 1:15
- 3:00 PM |
SESSION
VII |
Transplantation
Immunology |
| |
Chairpersons: |
Chang H. Kim, Ph.D
Jan Nolta, Ph.D. |
| |
1:15 - 1:35 PM |
Umbilical cord blood cytotoxic
T cells.
Jeffrey Miller, M.D., University of MN, Minneapolis, MN |
| |
1:35 - 1:55 PM |
Inflammatory cytokine induced immunosuppression in mesenchymal stem cells
Yufang Shi, DVM, Ph.D., Robert Wood Johnson Medical School, Piscataway,
NJ |
| |
1:55 - 2:15 PM |
Liver engraftment by transplanted
human progenitor cells with high aldehyde dehydrogenase activity in a
novel model, NOD/SCID/MPSVII mice.
Jan Nolta, Ph.D., University of California at Davis, Davis, CA |
| |
2:15 - 2:35 PM |
Chemokine receptors and migration
of cord blood-derived regulatory T cells.
Chang H. Kim, Ph.D., Purdue Cancer Center, West Lafayette, IN |
| |
2:35 - 3:00 PM |
Panel Discussion
Moderators: Dr. Kim, Dr. Nolta
Panelists: Kim, Nolta, Shi |
| 3:00 - 3:20 PM |
COFFEE BREAK in the
Exhibits |
| 3:20
- 5:00 PM |
SESSION
VIII |
Current Issues
in Cord Blood Banking |
| |
Chairpersons: |
Richard Champlin, M.D.
Dennis Confer, M.D. |
| |
3:20 -3:45 PM |
A summary review: Cord blood
banking - What is the state of the art?"
Pablo Rubinstein, M.D., New York Cord Blood Center, New York, NY |
| |
3:45 - 4:15 PM |
Progress in implementation of
the Stem Cell Therapeutic and Research Act of 2005: a report from the
Health Resources Services Administration (HRSA).
Robert Baitty, M.P.P., HRSA, Rockville, MD |
| |
4:15 - 4:45 PM |
The Food and Drug Administration
and UCB banking and transplantation.
Ellen Lazarus, M.D., US FDA, Rockville, MD |
| |
4:45 - 5:00 PM |
Panel Discussion
Moderator: Dr. Champlin, Dr. Confer
Panelists: Baitty, Lazarus, Rubinstein |
| 5:00
PM |
ADJOURN |
|
